Article info

Download PDFPDF
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial

Authors

  1. Correspondence to Dr Florian Heitz, AGO & Ev Kliniken Essen-Mitte, Essen, Germany; florian.heitz{at}gmx.net
View Full Text

Citation

Heitz F, Marth C, Henry S, et al
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial

Publication history

  • Accepted September 25, 2023
  • First published November 7, 2023.
Online issue publication 
December 04, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.